| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Gerard J Meskill, Craig W Davis, Donna Zarycranski, Markiyan Doliba, Jean-Charles Schwartz, Jeffrey M Dayn. Clinical Impact of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy: An Analysis of Randomized Placebo-Controlled Trials. CNS drugs. 2021-12-22. PMID:34935103. |
pitolisant, a selective histamine 3 receptor antagonist/inverse agonist, is indicated for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. |
2021-12-22 |
2023-08-13 |
Not clear |
| Pablo Medrano-Martinez, Rosa Peraita-Adrado. Neuropsychological Alterations in Narcolepsy with Cataplexy and the Expression of Cognitive Deficits. Journal of the International Neuropsychological Society : JINS. vol 26. issue 6. 2021-09-09. PMID:31826783. |
the objective of our study was to assess attention processes and executive function in patients with narcolepsy with cataplexy (nt1). |
2021-09-09 |
2023-08-13 |
Not clear |
| M Järvelä, V Raatikainen, A Kotila, J Kananen, V Korhonen, L Q Uddin, H Ansakorpi, V Kiviniem. Lag Analysis of Fast fMRI Reveals Delayed Information Flow Between the Default Mode and Other Networks in Narcolepsy. Cerebral cortex communications. vol 1. issue 1. 2021-07-24. PMID:34296133. |
in addition to sleep attacks and cataplexy, patients with narcolepsy commonly report cognitive symptoms while objective deficits in sustained attention and executive function have been observed. |
2021-07-24 |
2023-08-13 |
Not clear |
| Ryan K Tisdale, Akihiro Yamanaka, Thomas S Kilduf. Animal models of narcolepsy and the hypocretin/orexin system: Past, present, and future. Sleep. vol 44. issue 6. 2021-06-30. PMID:33313880. |
the identification of an inheritable narcolepsy phenotype in dogs in the 1970s allowed the establishment of a breeding colony at stanford university, resulting in studies that provided the first insights into the genetics and neurotransmitter systems that underlie cataplexy and rapid-eye movement sleep atonia. |
2021-06-30 |
2023-08-13 |
mouse |
| Ryan K Tisdale, Akihiro Yamanaka, Thomas S Kilduf. Animal models of narcolepsy and the hypocretin/orexin system: Past, present, and future. Sleep. vol 44. issue 6. 2021-06-30. PMID:33313880. |
although the discovery of the hypocretin/orexin neuropeptides in 1998 initially seemed unrelated to sleep/wake control, the description of the phenotype of the prepro-orexin knockout (ko) mouse as strongly resembling cataplexy, the pathognomonic symptom of narcolepsy, along with identification of a mutation in hypocretin receptor-2 gene as the source of canine narcolepsy, unequivocally established the relationship between this system and narcolepsy. |
2021-06-30 |
2023-08-13 |
mouse |
| Christian Franceschini, Chiara Fante, Maria Claudia Folli, Maria Filosa, Fabio Pizza, Elena Antelmi, Francesca Ingravallo, Giuseppe Plazz. Giving a voice to cataplectic experience: recollections from patients with narcolepsy type 1. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. vol 16. issue 4. 2021-06-23. PMID:32022668. |
the objective of this study was to assess the narratives from the recalled accounts of cataplexy attacks of patients with narcolepsy type 1 (nt1). |
2021-06-23 |
2023-08-13 |
Not clear |
| Bei Huang, Tao Xu, Zongwen Wang, Kun Chen, Jihui Zhang, Zhongxin Zhao, Jianhua Zhuang, Huijuan W. The clinical characteristics of cataplectic attack in narcolepsy type 1. Sleep medicine. vol 77. 2021-06-21. PMID:31607435. |
this study was conducted to clarify the clinical characteristics of cataplexy by staging, and to further analyse the correlations of clinical features and cataplectic stages in patients with narcolepsy type 1 (nt1). |
2021-06-21 |
2023-08-13 |
Not clear |
| Anelia Dietmann, Michael P Horn, Mink S Schinkelshoek, Rolf Fronczek, Anke Salmen, Panagiotis Bargiotas, Gert J Lammers, Ramin Khatami, Claudio L A Bassett. Conventional autoantibodies against brain antigens are not routinely detectable in serum and CSF of narcolepsy type 1 and 2 patients. Sleep medicine. vol 75. 2021-06-21. PMID:32858359. |
narcolepsy with cataplexy (nt1) is a chronic hypothalamic disorder with a presumed immune-mediated etiology leading to a loss of hypocretin neurons. |
2021-06-21 |
2023-08-13 |
Not clear |
| Ying Sun, Meng Li. Hypothalamic MCH Neuron Activity Dynamics during Cataplexy of Narcolepsy. eNeuro. vol 7. issue 2. 2021-06-18. PMID:32303567. |
hypothalamic orexin (hypocretin, hcrt) deficiency causes sleep disorder narcolepsy with cataplexy in humans and murine. |
2021-06-18 |
2023-08-13 |
Not clear |
| Maria Pia Giannoccaro, Rocco Liguori, Giuseppe Plazzi, Fabio Pizz. Reviewing the Clinical Implications of Treating Narcolepsy as an Autoimmune Disorder. Nature and science of sleep. vol 13. 2021-05-20. PMID:34007229. |
narcolepsy type 1 (nt1) is a lifelong sleep disorder, primarily characterized clinically by excessive daytime sleepiness and cataplexy and pathologically by the loss of hypocretinergic neurons in the lateral hypothalamus. |
2021-05-20 |
2023-08-13 |
Not clear |
| Mihoko Shimada, Taku Miyagawa, Tohru Kodama, Hiromi Toyoda, Katsushi Tokunaga, Makoto Hond. Metabolome analysis using cerebrospinal fluid from narcolepsy type 1 patients. Sleep. vol 43. issue 11. 2021-04-14. PMID:32412602. |
narcolepsy type 1 (nt1) is a hypersomnia characterized by excessive daytime sleepiness and cataplexy. |
2021-04-14 |
2023-08-13 |
human |
| Laury Quaedackers, Jan De Wit, Sigrid Pillen, Merel Van Gilst, Nikolaos Batalas, Gert Jan Lammers, Panos Markopoulos, Sebastiaan Overee. A Mobile App for Longterm Monitoring of Narcolepsy Symptoms: Design, Development, and Evaluation. JMIR mHealth and uHealth. vol 8. issue 1. 2021-04-01. PMID:31909723. |
although narcolepsy is primarily characterized by excessive daytime sleepiness and cataplexy (loss of muscle control triggered by emotions), patients may suffer from hypnagogic hallucinations, sleep paralysis, and fragmented night sleep. |
2021-04-01 |
2023-08-13 |
Not clear |
| Anna A Rogers, Lauren M Aiani, Lou T Blanpain, Sun Yuxian, Renee Moore, Jon T Willi. Deep brain stimulation of hypothalamus for narcolepsy-cataplexy in mice. Brain stimulation. vol 13. issue 5. 2021-03-22. PMID:32320748. |
narcolepsy type 1 (nt1, narcolepsy with cataplexy) is a disabling neurological disorder caused by loss of excitatory orexin neurons from the hypothalamus and is characterized by decreased motivation, sleep-wake fragmentation, intrusion of rapid-eye-movement sleep (rems) during wake, and abrupt loss of muscle tone, called cataplexy, in response to sudden emotions. |
2021-03-22 |
2023-08-13 |
mouse |
| Vivien C Aba. Profile of Solriamfetol in the Management of Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea: Focus on Patient Selection and Perspectives. Nature and science of sleep. vol 13. 2021-02-06. PMID:33531850. |
for excessively sleepy adult patients with osa despite primary treatment or narcolepsy patients without cataplexy, solriamfetol may be used as initial therapy or as replacement therapy in patients who fail treatment or experience unacceptable side effects with modafinil, armodafinil, pitolisant, or stimulants. |
2021-02-06 |
2023-08-13 |
Not clear |
| Gaia Pellitteri, Pierluigi Dolso, Mariarosaria Valente, Gian Luigi Gigl. Orgasmolepsy in Narcolepsy Type 1 Responsive to Pitolisant: A Case Report. Nature and science of sleep. vol 12. 2021-01-11. PMID:33408544. |
we describe a case of a young male patient with narcolepsy type 1 (nt1), who developed generalized cataplexy attacks during sexual intercourses, on which we have obtained a satisfactory control with pitolisant. |
2021-01-11 |
2023-08-13 |
Not clear |
| Ali Seifinejad, Sha Li, Marie-Laure Possovre, Anne Vassalli, Mehdi Taft. Hypocretinergic interactions with the serotonergic system regulate REM sleep and cataplexy. Nature communications. vol 11. issue 1. 2020-12-10. PMID:33247179. |
loss of muscle tone triggered by emotions is called cataplexy and is the pathognomonic symptom of narcolepsy, which is caused by hypocretin deficiency. |
2020-12-10 |
2023-08-13 |
mouse |
| Mahmoud M A Abulmeaty, Ahmed S BaHammam, Ghadeer S Aljuraiban, Ali M Almajwal, Mona S Aldosar. Measured resting metabolic rate, respiratory quotient, and body composition in patients with narcolepsy: a preliminary report of a case-control study. Scientific reports. vol 10. issue 1. 2020-12-08. PMID:32620831. |
the narcolepsy patients were subdivided into two subgroups (n = 7/each): those with cataplexy (nt1) and those without cataplexy (nt2). |
2020-12-08 |
2023-08-13 |
Not clear |
| Catherine A McCall, Nathaniel F Watso. Therapeutic Strategies for Mitigating Driving Risk in Patients with Narcolepsy. Therapeutics and clinical risk management. vol 16. 2020-11-20. PMID:33209031. |
narcolepsy is a central nervous system hypersomnia disorder characterized by uncontrollable episodes of daytime sleep, sleep state instability, and cataplexy (sudden loss of muscle tone precipitated by emotion). |
2020-11-20 |
2023-08-13 |
Not clear |
| Michael W Cali. Update on the treatment of narcolepsy: clinical efficacy of pitolisant. Nature and science of sleep. vol 9. 2020-10-01. PMID:28490912. |
in 60-70% of individuals with narcolepsy, it is also characterized by cataplexy or a sudden loss of muscle tone that is triggered by positive or negative emotions. |
2020-10-01 |
2023-08-13 |
Not clear |
| Silvia Leiva, Jimena Madrazo, Claudio Podest. Narcolepsy with cataplexy and hyperthyroidism sudden appeared after H1N1 vaccination. Sleep science (Sao Paulo, Brazil). vol 11. issue 1. 2020-09-30. PMID:29796199. |
narcolepsy type 1 (nt1) is a chronic sleep disorder, characterized by excessive daytime sleepiness, cataplexy and fragmented nocturnal sleep. |
2020-09-30 |
2023-08-13 |
Not clear |